OBI Pharma enters collaboration with GlyTech to expand GlycOBI® enabling technologies outreach in Japan and to advance glycan production

CAR-T Digest - August 2020

Weekly Digest - December 2024

23 Dec 2024: OBI Pharma enters collaboration with GlyTech to expand GlycOBI® enabling technologies outreach in Japan and to advance glycan production

OBI Pharma, a global oncology company, and GlyTech, a Japanese manufacturer specializing in glycan production and chemical glycosylation technologies, have entered into two agreements: a Marketing Agreement and a Material Transfer Agreement
Under the Marketing Agreement, OBI grants GlyTech the rights to market and promote OBI’s GlycOBI® ADC enabling technologies, powered by EndoSymeOBI®, to pharmaceutical and biotech partners in Japan
GlyTech will also become a key supplier of glycans in Japan for ADC applications
The Material Transfer Agreement allows OBI to transfer cutting-edge materials to GlyTech for research purposes, specifically to advance the efficient production of glycans for use in ADCs